
This version is available at https://strathprints.strath.ac.uk/55237/

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.uk
Viperatoxin-II: A novel viper venom protein as an effective bactericidal agent

Ramar Perumal Samy a,b,c,*, Bradley G. Stiles d,e, Arunachalam Chinnathambi f, M.E. Zayed f, Sulaiman Ali Alharbi f, Octavio Luiz Franco g,h, Edward G. Rowan i, Alan Prem Kumar j,k,l,m, Lina H.K. Lim c, Gautam Sethi t,i,j

a Venon and Toxin Research Programme, Department of Anatomy, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore 117597
b Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, NUHS, National University of Singapore, Singapore 117597
c Department of Physiology, NUS Immunology Programme, Centre for Life Sciences, Yong Loo Lin School of Medicine, NUHS, National University of Singapore, Singapore 117456
d Integrated Toxinology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702-5011, USA
e Department of Biology, Wilson College, 1015 Philadelphia Avenue, Chambersburg, Pennsylvania 17201, USA
f Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 14511, Saudi Arabia
g Universidade Católica de Brasilia, Centro de Andilises Protéomicas e Bioquímicas, Pós-Graduação em Ciências Genômicas e Biotecnologia UCB, Brasília-DF, Brazil
h 5-Inova Biotech, Pos-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande, MS, Brazil
i Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, United Kingdom
j Department of Pharmacology, Yong Loo Lin School of Medicine, National University Singapore, Singapore 117600
k Cancer Science Institute, National University of Singapore, Singapore 117599
l School of Biomedical Sciences, Curtin University, Western Australia, Australia
m Department of Biological Sciences, University of North Texas, Denton, TX, USA

ARTICLE INFO
Article history:
Received 16 June 2015
Revised 12 October 2015
Accepted 14 October 2015

Keywords:
Bactericidal
daboia russelli russelli
Vipertoxin-I
Vipertoxin-II

ABSTRACT
Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) have become a rising threat to public health. There is an urgent need for development of promising new therapeutic agents against drug resistant bacteria like S. aureus. This report discusses purification and characterization of proteins from Indian Russell’s viper snake venom. Novel 15-kDa proteins called “Viperatoxin” (VipTx-I and VipTx-II) were extracted from the whole venom and evaluated using in vitro antimicrobial experiments. The N-terminal amino acid sequence of “Viperatoxin” showed high sequence homology to daboiatoxin isolated from the same venom and also matched phospholipase A2 (PLA2) enzymes isolated from other snake venoms. In an in vitro plate assay, VipTx-II but not VipTx-I showed strong antimicrobial effects against S. aureus and Burkholderia pseudomallei (KHW & TES), Proteus vulgaris and P. mirabilis. The VipTx-II was further tested by a broth-dilution assay at 100–3.125 μg/ml concentrations. The most potent bactericidal effect was found at the lowest dilutions (MICs of 6.25 μg/ml) against B. pseudomallei, S. aureus and P. vulgaris (MICs of 12.25 μg/ml). Electron microscopic investigation revealed that the protein-induced bactericidal potency was closely associated with pore formation and membrane damage, even at the lowest concentrations (<20 μg/ml). The toxin caused a low level of cytotoxic effects as observed in human (THP-1) cells at higher concentrations. Molecular weight determinations of VipTx-II by sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed one major, along with a few minor bands. The results indicate that VipTx-II plays a significant role in bactericidal and membrane damaging effects in vitro. Non-cytotoxic properties on human cells highlight it as a promising candidate for further evaluation of antimicrobial potential in vivo.

© 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA) have become a very important threat to public health [1]. It can cause severe disease, including necrotizing fasciitis, sepsis, endocarditis and pneumonia [2]. The Gram-negative bacterium *Burkholderia pseudomallei* causes not only human melioidosis [3] but also community-acquired bacteraemic pneumonia [4], septicemias and also high mortality due to septic shock [5]. The presence of septicaemia (44%) and major organ failure (48%) results in death as well as relapse in patients with inappropriate treatment [6]. *B. pseudomallei* are intrinsically resistant to many antimicrobial agents including first and second generations of cephalosporins, penicillin, macrolides, colistin, rifamycins and aminoglycosides [7]. The above drugs cause serious side effects such as nephrotoxicity and neurotoxicity. Therefore, there is an urgent need for the development of promising new therapeutic agents against drug-resistant bacteria.

Antimicrobial proteins and peptides are produced by all forms of living organisms and represent a novel class of antibiotics to treat infectious diseases [8]. Snake venoms are an extremely rich source of pharmacologically-active peptides with considerable clinical potential [9,10]. Snake venoms from *Viperidae* species possess significant bactericidal inhibition [11]. Previous studies show that various venom proteins possess significant antimicrobial activity [12,13].

Several types of secreted phospholipase A\(_2\) (sPLA\(_2\)) reportedly exert potent bactericidal actions dependent upon their enzymatic activities [14]. sPLA\(_2\)s have been implicated in lipid digestion to enhance host defence mechanisms that include antibacterial properties [15]. Many studies have demonstrated that the type-IIA sPLA\(_2\) is an endogenous antibiotic-like protein that kills bacteria [16]. The acidic PLA\(_2\) from *Porphyridium nasutum* snake venom has antibacterial activity [17]. PLA\(_2\) homologues present in snake venoms, known as Lys49 PLA\(_2\)s [18], also have bactericidal activity. Myotoxic PLA\(_2\) enzymes are also known to induce bactericidal activity against *Escherichia coli* and *S. aureus* [19,20]. The bactericidal effect of PLA\(_2\) isolated from *Bothrops* snake venoms is reportedly due to its catalytic activity [21] but according to Lomonte et al. [19], the catalytically inactive myotoxic Lys49-PLA\(_2\) can also induce a bactericidal effect. PLA\(_2\) myotoxins purified from crotalidae snake venoms, including both Lys49 and Asp49-type isoforms, are bactericidal and thus indicate a common mechanism of action for the type-IIA PLA\(_2\) protein family. There are not only bactericidal properties of short cationic peptides derived from a snake venom Lys49-PLA\(_2\) [20,22], but also anti-HIV [23] and anti-fungal activity of a PLA\(_2\)-derived synthetic peptide variant against *Candida albicans* [24]. A group of antimicrobial peptides derived from the C-terminal sequence 115–129 of myotoxin II and its triple Tyr–Trp substituted peptide p115-W3, have been reported previously [22]. More tryptophan substitutions increased microbicidal activity with the latter mechanism of action determined by electron microscopy.

2. Experimental procedures

2.1. Chemicals

Chemicals and solvents were obtained from Fluka Chemie GmbH (Deisenhofen, Germany) and Merck (Darmstadt, Germany). Electrophoresis materials such as bromophenol blue, 2-mercaptoethanol, glycerol, sodium dodecyl sulphate (SDS), Coomassie Brilliant Blue R-250, 30% acrylamide/bisacylamide, ammonium persulphate and N,N,N,N-tetramethylethylenediamine (TEMED) were from Bio-Rad (Hercules, CA, USA). Dye reagent for protein assay (Bio-Rad) and all other reagents were from Sigma (St Louis, MO, USA).

2.2. Extraction of venom

Lyophilized venom of *D. russelli russelli* (Indian Russell’s viper) was purchased from commercial sources (Venom Supplies Pte Ltd, Tanunda, South Australia). The venom samples were collected in a sterile manner under strict laboratory conditions, and were transferred to microcentrifuge tubes, immediately frozen and lyophilized. The dried venom was normally packed and stored dark at −20 °C.

2.3. Purification of protein

Lyophilized whole crude venom (500 mg) of *D. russelli russelli* was dissolved with 10 ml of 50 mM (pH 7.4) Tris–hydrochloric acid (Tris–HCl) buffer. The suspension was centrifuged at 500 g at 4 °C for 15 min and filtered through a 0.22 μm syringe filter (Nalge Nunc International, Rochester, NY, USA) to remove any colloidal or particulate material. Aliquots of the yellowish clear supernatant were loaded on a Superdex G-75 column (1.6 × 40 cm; Amersham Pharmacia (GE Healthcare, Upsala, Sweden) previously equilibrated with the same buffer (50 mM Tris–HCl, pH 7.4). Fractions (2 ml) were collected at a flow rate of 15 ml/h. The absorbance of all fractions was monitored at 280 nm. Eight fractions (RV1–RV8) were collected from the single pool of venom fractionated by a G-75 gel-filtration column and aliquots taken for testing antibacterial and PLA\(_2\) activities, as well as protein measurement. The fraction (RV5) with highest antibacterial and PLA\(_2\) activities was further separated by using a C18 sepharose column (250 × 4.6 mm, 300 Å, 5 μm) with reverse-phase (RP)-high performance liquid chromatography (RP-HPLC) and resolved into four protein fractions (RV-F1, RV-F2, RV-F3, RV-F4) monitored at 254 nm. Of which, the active fraction RV-F4 was further purified by C8 sepharose column (Jupiter Phenomenex, Torrance, CA, USA) in 0.1% trifluoroacetic acid (TFA) in water eluted with a linear gradient of 80% acetonitrile (ACN) in 0.1% TFA at 215 nm. Pure protein fractions (VipTx-I and VipTx-II) were collected separately with a FC905 B fraction collector (0.5 ml per min) and designated as “viperatoxin”.
2.4. Protein assay

Protein concentrations of samples were determined by the method of Bradford [35], as modified by BioRad Laboratories (San Diego, CA, USA). Purified PLA\textsubscript{2} samples were prepared at 4.0 mg/ml concentrations, using bovine gamma-globulin for the standard curve.

2.5. Protein analysis by SDS–PAGE

The purity of isolated VipTx-I and VipTx-II was verified by SDS–PAGE (4.5 stacking gel/14% separating gels – Tris-glycine running buffer) according to Laemmli, [36]. The fractions were diluted 1:1 with sample buffer (0.12 M Tris–HCl, pH 6.8 containing 2% SDS, 5% 2-mercapethanol, 10% glycerol, 0.02% bromophenol blue) and heated for 5 min in a boiling water bath. Electrophoresis was carried out at a constant current 20 mA for 2.5 h. The gel was fixed with 5% acetic acid overnight and stained for 2 h in 0.1% Coomassie Brilliant Blue R-250 in 5% acetic acid. Destaining was carried out in a solution containing 35% methanol and 7% acetic acid until the background became clear. The molecular weights of protein bands were determined using Bio-Rad SDS molecular weight markers.

2.6. Determination of molecular mass

Molecular weight analyses were performed primarily using a Perspective Biosystem matrix-assisted laser desorption ionization-time of flight (MALDI-TOF/MS) voyager-DE mass spectrometer (Framingham, MA), operated in delayed extraction mode. The enzymes (0.1 µl applied on a clean matrix plate) were analyzed using a saturated solution of α-cyano-4-hydroxycinnamic acid in acetone containing 1% TFA (Sigma, St. Louis, MO, USA). The proteins were selected in the mass range of 10,000–50,000 Da. Spectra were calibrated using calibration mixture 2 of the sequazyme peptide mass standards kit (AB SCIEX). MS-Fit was used for searches in the National Center for Biotechnological Information (NCBI) database. MALDI-TOF mass spectrometry was used for molecular weight determination.

2.7. Analysis of sequencing

Suitable enzymes were subject to N-terminal sequencing by Edman degradation using an Applied Biosystems 494 pulsed liquid-phase sequencer, equipped with an on-line 120 A PTH-amino acid analyzer at the National University of Singapore (NUS), Singapore. The resulting amino acid (AA) sequences were submitted to Basic Local Alignment Search Tool (BLAST) for sequence similarity search (http://web.expasy.org/cgi-bin/blast/blast.pl) by using the ExPASy World Wide Web (WWW) molecular biology server of the Swiss Institute of Bioinformatics (SIB). When the N-terminal sequences of VipTx-I and VipTx-II were blasted for sequence similarity. The VipTx-I and VipTx-II masses were different from that reported for D. russelli russelli (Indian Russell’s viper) in an earlier report [34].

2.8. PLA\textsubscript{2} enzyme activity (PLA\textsubscript{2})

The Cayman chemical secretory PLA\textsubscript{2} (sPLA\textsubscript{2}) assay kit was used for measuring PLA\textsubscript{2}. The PLA\textsubscript{2} enzyme activity is also converted to µmoles of fatty acid released per min per mg phospholipase by decreased absorbance produced by a known amount of acid. A decrease in absorbance of 0.1 was obtained with 0.025 µmoles of HCl in the reaction mixture [37].

2.9. Antimicrobial assay

Clinical isolates of Gram-negative bacteria E. coli (ATCC 25922), Enterobacter aerogenes, Proteus vulgaris (ATCC27968), Proteus mirabilis (ATCC35491), Pseudomonas aeruginosa (ATCC27853), B. pseudomallei (TES21), B. pseudomallei (KHW22) and the Gram-positive bacterium S. aureus (ATCC 29213) were obtained from the Department of Microbiology, Yong Loo Lin School of Medicine, NUS, Singapore. The following antimicrobial agents: Streptomycin (30 µg/disc), Chloramphenicol (30 µg/disc), Ceftazidime (30 µg/disc), Penicillin (10 units) and Vancomycin (10 units) (Becton Dickinson Labware, USA) were included as positive controls. Blank discs with sterile double-distilled water served as a negative control [38]. Mueller Hinton (MH) and Tryptic Soya (TS) agar medium was purchased from Oxoids, UK. The bacterial cultures were spread and allowed to grow overnight at 37°C on 20 ml MH or TS agar (pH 7.4) plates (100 mm diameter) prior to storage at 4°C. Antimicrobial susceptibility was tested according to the method of Bauer et al [39]. Gram-negative bacteria (E. coli, E. aerogenes, P. vulgaris, P. mirabilis, P. aeruginosa) and Gram-positive bacteria (S. aureus) were grown in MH broth, while B. pseudomallei (TES and KHW) were grown in TS broth (OD\textsubscript{600} 1.0) which corresponds to 1.5 × 10\textsuperscript{8}–3.2 × 10\textsuperscript{8} colony forming units (CFU/ml). Bacteria were incubated with VipTx-I and VipTx-II at 100 µg/ml concentrations on MH and TS solid agar plates incubated for 24 h at 37°C. Bacterial inhibition zones were measured as millimeters in diameter (inhibitory zones).

2.9.1. Minimum inhibitory concentrations (MICs)

Preparation of bacterial inoculums from frozen suspensions were sub-cultured onto MH and TS agar plates and passaged twice prior to susceptibility testing. The bacteria were grown in MH broth for 5–7 h (exponential phase) before adjusting concentration to a 0.5 McFarland turbidity standard. The adjusted bacterial cultures were diluted to approximately 3.2 × 10\textsuperscript{6} CFU/ml [17]. MICs were determined by the broth micro-dilution techniques [40], for which serial dilutions of VipTx-I and VipTx-II were prepared at 100, 50, 25, 12.5, 6.125, 3.078 µg/ml in 96-well microtiter trays with appropriate broths (MH & TS), whereas multi-drug resistant B. pseudomallei (TES & KHW) was tested at 3.078–100 µg/ml concentrations in TS broth. Three replicates were used for each dilution series that included control wells containing bacteria without VipTx-I or VipTx-II. A 200 µl aliquot of the 10\textsuperscript{6} CFU/ml was added to each well (96-well plates) with 50 µl of VipTx-II. The culture trays were incubated at 37°C for 24 h, the inhibition of bacterial growth was determined by measuring the absorbance at 600 nm (Sunrise Precision Microplate reader, Tecan Group Ltd, Mannedorf, Switzerland). The MICs were taken as the lowest concentration of VipTx-I or VipTx-II that inhibited visible growth. The results given are mean values of three independent determinations. After MIC measurement, each dilution of proteins treated with bacterial samples (20 µl) was spread on to MH and TS agar plates and incubated at 37°C for 24 h. Minimum bactericidal concentrations (MBCs) were assayed at 100–3.125 µg/ml concentrations.

2.9.2. Scanning electron microscopy (SEM)

The structural changes induced by VipTx-I or VipTx-II (100-3.078 µg/ml) on S. aureus, B. pseudomallei (KHW & TES), E. aerogenes, P. vulgaris, and P. mirabilis were studied using SEM as described earlier [41]. Each protein sample (50 µl) contained (bacteria) pre-incubated together for 30 min at 37°C. The control received equivalent volumes of MH broth containing bacteria. After removing a small portion of these samples for CFU/ml measurements, the remainder was centrifuged for 10 min at 2800g. Pellets were resuspended.
and fixed with an equal volume of 2.5% glutaraldehyde in 1 mM phosphate buffer (pH 7.4) for 1 h. Immediately following addition of fixative solution, the sample tubes were mixed by gently inverting them up and down for several minutes to prevent clumping of cells. The cells were post-fixed for an additional hour with 1% osmium tetroxide (OsO₄) and washed thrice in PBS. Samples (1 μl) were pipetted onto a sterile cover glass coated with poly-L-lysine and left for 20–30 min. The section was dehydrated by a series of alcohol baths (25%, 50%, 75%, 90% 100%). The samples were transferred from 100% ethanol to a critical point dryer (Balzers CPD-030, Bal-Tec AG, Vaduz, Liechtenstein), and dried using liquid carbon dioxide. The samples were mounted on aluminum specimen supports with carbon adhesive tabs, and coated with a 10–15 nm thickness of gold using a sputter coater SC D005 (Bal-Tec, EM Technology and Application, Liechtenstein). Samples were examined with a Philips XL 30 FEG SEM (Electron Microscopy, Japan) using an accelerating voltage of 5–10 kV.

2.9.3. Transmission electron microscopy (TEM)
The structural changes induced by VipTx-II on S. aureus and B. pseudomallei (KHW) were studied using TEM as described earlier [42]. Bacterial cells suspended in 10 mM phosphate buffer (pH 7.4) treated with VipTx-II (6.25 μg/ml) were fixed with an equal volume of 2.5% glutaraldehyde in 10 mM phosphate buffer, pH 7.4. The fixed samples were stored overnight at 4 °C in fixative solution. The suspended cells were rinsed with 10 mM phosphate buffer, and dehydrated through a graded series of ethanol (25–100%). During the entire filtration, rinsing, and dehydration process, cells were covered with fluid to prevent air drying. The samples were transferred from 100% ethanol in to a critical point dryer, and dried using carbon dioxide. The samples were mounted on aluminum specimen supports with carbon adhesive tabs, and coated with gold-palladium metal (60:40 alloy and 15 nm thickness) using a Hummer X sputter coater (Bal-Tec, EM Technology and Application, Liechtenstein). Samples were examined with a Philips XL 30 FEG SEM (Electron Microscopy, Japan) using an accelerating voltage of 5–10 kV.

2.9.4. Cell proliferation and cytotoxicity (MTT based) assay
The human macrophage cells (THP-1) were obtained from ATCC, (Virginia, USA). Sterile Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal Bovine Serum (FBS), and 10 mM HEPES were purchased from the National University Medical Institute (NUMI), Singapore. All chemicals were of analytical and cell culture grade. THP-1 cells were cultured in 72 cm² flasks at a density of 10⁵ cells/ml in DMEM culture medium supplemented with 10% FBS, and 1 ml of HEPES. The cells adhered to the flask bottom overnight at 37 °C in a humidified atmosphere of 5% CO₂ and 95% air. The culture medium was changed four times a week. To analyze the initial events of VipTx-I and VipTx-II upon cell viability, the proteins were applied to THP-1 cells at different concentrations (10,000–39 μg/ml) with varied time intervals (24 and 48 h), tetrazolium dye added and incubated for 30 min. Cell proliferation was assessed by measuring optical density (OD) using an ELISA plate reader at 490 nm. All assays were performed in triplicates and repeated thrice.

2.9.5. Cytolytic assay by lactate dehydrogenase (LDH)
Cytolytic effects of proteins on human acute monocyctic leukemia cells were evaluated by measuring the release of LDH enzyme using a cytotoxicity detection kit (Roche Mannheim, Germany). Proteins (VipTx-I and VipTx-II) were added to THP-1 cells (10⁴ cells/well) cultured on 96-well plates in DMEM medium (NUMI, Singapore) supplemented with 10% (vol/vol) FBS. The proteins (10,000–39 μg/ml) were added and further incubated with cells for 24 and 48 h. A 200 μl aliquot of the centrifuged supernatant obtained from each well was used for the quantification of cell death and lysis, based on the measurement of LDH activity released from the cytosol of damaged cells into the supernatant. The assay was performed in triplicate.

2.9.6. Statistical analysis
The results (mean ± S.D., n = 5) were statistically analyzed by one way ANOVA with repeated measures used to analyze factors influencing the size of the growth inhibition zones. The level of statistical significance was at *P < 0.01 and **P < 0.05 etc.

3. Results

3.1. Purification and characterization of protein
Viperatoxin was purified from the venom of Russell’s viper (D. russelli) by gel-filtration chromatography on a Superdex G-75 column, yielding eight major protein peaks (Fig. 1A). All of the fractions (RV1 to RV8) were assayed for antibacterial activities, of which RV5 showed significant antibacterial and PLA₂ activity versus RV4. The active fraction RV5 was further fractionated by reverse phase (RP) chromatography on Sepharose (C18 column), and resolved into four further fractions, namely RV-F1 to RV-F4 (Fig. 1B). The most active antibacterial fraction (RV-F4) was applied to Sepharose C18 and C8 reverse phase columns and resolved into two major purified proteins (Fig. 1C and D), subsequently designated as “Viperatoxins” VipTx-I and VipTx-II. The VipTx-II showed more phospholipase A₂ enzymatic activity than the VipTx-I. However, the protein purity was assessed by mass spec MALDI-TOF/MS analysis showing the actual mass of VipTx-I (13669.93 daltons) and VipTx-II (13869.05 daltons) (Fig. 1E and F). Protein purity was assessed by SDS–PAGE, and molecular weight was estimated to be approximately 15 kDa (Fig. 1G).

3.2. Phospholipase A₂ enzyme activity
Phospholipase A₂ (PLA₂) enzyme was known to be a major component of snake venoms showed important toxic and pharmacological effects. In this study, eight PLA₂ enzyme fractions were isolated from the crude venom such as RV1–RV8, of which fraction RV5 was displayed higher enzyme activity/bactericidal potency further purified by reverse-phase chromatography (C18 column) resolved into four fractions (RV-F1–RV-F4). Similarly, enzymatically the most active fraction (RV-F4) was separated by C8 columns and yielded VipTx-I/VipTx-II proteins. Fascinatingly, there was not only a higher level of PLA₂ enzymatic activity but also high proteins levels of VipTx-II determined in this assay system (Fig. S1 A and B).

3.3. Analysis of sequencing
The N-terminal amino acid (AA) residues of VipTx-I and VipTx-II were sequenced, and compared with those found in the expert protein analysis system (ExPASY) proteomics database using a basic local alignment search tool (BLAST) search alignment with several types of snake venom PLÁs (Table. 1). The AA sequences were matched exactly with the available sequences and its protein masses varied from the existing snake venom PLÁS. The sequence comparison shows that VipTx-II shares greatest sequence identity (60–86%) with a PLÁ from other vipers, and a high degree of sequence homology exists with the group RV-VIIIA PLÁs. In particular, the N-terminal residues of VipTx-II matched with existing PLÁs, but slight modification of one or two new AA residues found in the sequences are most likely due to post translational modifications. The VipTx-II also shared much sequence homology with the Asp-49 enzymes from several species. The BLAST search
was matched with previously reported basic svPLA$_2$s of the Viperidae. The N-terminal sequences (VipTx-II) were 91% identical to sp|P86368|PA23_DABRR (showing 5th in the alignment). These basic amino acids and hydrophobicity are essential for enhanced antimicrobial activity. Also, to the best of our knowledge, this is the first detailed report on the antimicrobial activity of Indian viper venom proteins along with their unique mechanisms of action.

3.4. In vitro antimicrobial activity

Purified proteins (VipTx-I and VipTx-II) were tested for their antibacterial properties against Gram-positive and Gram-negative bacteria at a 100 μg/ml concentration. The enzyme exhibited broad spectrum activity against a wide range of pathogenic organisms. The VipTx-II enzyme showed very strong antimicrobial action.
against S. aureus, B. pseudomallei (KHW), P. vulgaris, E. aerogenes, and P. mirabilis (Fig. 2A and B). The most promising activity of VipTx-II was compared with standard antibiotics (i.e., Cefazolin, Chloramphenicol, Penicillin, Streptomycin, and Vancomycin). The VipTx-II was further assayed against multi-drug resistant (MDR) B. pseudomallei (strain of KHW) and S. aureus. The inhibitory potential of VipTx-II was equal against both types of bacteria; however, this protein was slightly more effective in controlling the growth of B. pseudomallei at 10 μg/ml (Fig. 2C).

3.4.2. Minimum inhibitory concentrations (MICs)

The MICs of proteins (VipTx-I and VipTx-II) were determined by broth-dilution assay with initial sample concentrations of 100, 50, 25, 12.5, 6.25, 3.125 and 1.56 μg/ml tested against Gram-positive and Gram-negative strains, including B. pseudomallei (TES & KHW). The MIC values are expressed as the lowest concentration that caused 100% bacterial growth inhibition. The VipTx-II exhibited marked activity against B. pseudomallei KHW & TES (MICs of 6.25 μg/ml), S. aureus, (MICs 6.25 μg/ml), P. mirabilis (MICs of 12.5 μg/ml), P. vulgaris (MICs of 25 μg/ml), whereas E. coli, E. aerogenes and P. aeruginosa showed weaker inhibitory MIC effects at all dilutions (100–1.56 μg/ml) shown in Fig. 3A–H. Interestingly, VipTx-II exhibited significant inhibition at the lowest dilution against B. pseudomallei and S. aureus (MIC of 6.125 μg/ml). The bactericidal (killing) potential of proteins was further quantified by a TS and MH broth dilution method (100–1.56 μg/ml) as shown in Table 2. The MBCs result revealed that VipTx-II exerted most significant inhibition against KHW strains of B. pseudomallei and S. aureus at the lowest dilutions (MBC 6.125 μg/ml) versus bacterial control. The VipTx-I only weakly killed multi-drug resistant strains of B. pseudomallei at all tested concentrations.

3.4.3. Mechanisms of action for VipTx-II

Smooth membrane structure was clearly evident in control bacteria without treatment, B. pseudomallei (KHW) treated with VipTx-II resulted in numerous mushroom-shaped blebs, thickening irregular shapes and retraction of cytoplasm, while bacteria appeared to be losing cell contents particularly at the division septa after 24 h (Fig. 4A & B). Particularly after the treatment of VipTx-II with Gram-positive (S. aureus), while fibrous and presumably cell contents (granular material) appeared to exude from the damaged membranes (Fig. 4C-F) and the inner membrane was difficult to discern. Bacteria treated with VipTx-II also lost of the membrane structure and the formed of blebs in
B. pseudomallei strain KHW, clearly shown in transmission electron microscopy (Fig. 4G and H) than the control (ctrl). The ultrastructural studies have proven the pore-forming action of VipTx-II enzyme on bacteria. Generally, viper proteins induced specific structural and morphological changes versus untreated bacterial controls.

3.5. Morphological and cellular toxicity

Cytotoxicity results indicated that VipTx-II did not affect the cell viability up to a concentration of 1000 μg/ml. Human macrophages (THP-1) were not affected particularly at 625 μg/ml in a cytotoxicity assay. Exposure to VipTx-II revealed minimal
Fig. 3. The MICs values were determined by a modified micro-broth dilution assay using VipTx-II against Gram-negative and Gram-positive bacteria. (A–H) VipTx-II inhibits *S. aureus* and *B. pseudomallei* in a dose-dependent fashion and less number of colonies was observed. The activity of VipTx-II was 10-fold greater against *S. aureus* and *B. pseudomallei*, each breaking point represents the mean of triplicate samples. VipTx-II inhibits *S. aureus* (MICs 6.125 μg/ml), *B. pseudomallei* KHW & TES (MICs 6.125 μg/ml), *Proteus mirabilis* (MICs 12.5 μg/ml) and *Proteus vulgaris* (MICs 25 μg/ml) more effectively versus *P. aeruginosa*, *Escherichia coli* and *Enterobacter aerogenes*. 
cytotoxicity up to 625 μg/ml concentrations. The optimum dose of VipTx-II gradually decreased THP-1 cell proliferation after treatment with enzymes (Fig. 5A and B). However, cell survival decreased with increasing concentrations of VipTx-I from 39 to 10,000 μg/ml and EC50 1250 μg/ml (Fig. 5C and D). The morphological changes of the cells revealed that membrane disruption, lysis and significant cell death was evident at a 2500 μg/ml concentration of VipTx-I in a time and dose dependent (24 and 48 h) manner. Sixty percent of the THP-1 cells were inhibited by the exposure of VipTx-I after 48 h than in the control. However, the cytolytic levels were at higher concentrations up to 2500 μg/ml (Fig. 5E–H).

3.6. LDH assay

The LDH results revealed that THP-1 cells exposed to VipTx-II were not affected up to 1250 μg/ml concentrations (Fig. 6A and B). Significant cell death is evident at higher concentration (2500 μg/ml) in a dose and time-dependent manner (24 and 48 h), as a result there is more LDH release into the media. However, the cell proliferation was not affected especially at the optimal dose of VipTx-II (EC50 1250 μg/ml) than the VipTx-II (Fig. 6C and D). The optimum dose that inhibited bacterial proliferation did not affect the THP-1 cells.

4. Discussion

Bacterial resistance is a significant problem for treating infections, and thus there is a keen interest in research directed

Table 2

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>MBCs [μg/ml]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>VipTx-I</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>100</td>
</tr>
<tr>
<td>Enterobacter aerogenes</td>
<td>100</td>
</tr>
<tr>
<td>Proteus vulgaris</td>
<td>50</td>
</tr>
<tr>
<td>Proteus mirabilis</td>
<td>50</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>100</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>50</td>
</tr>
<tr>
<td>Burkholderia pseudomallei (strain KHW)</td>
<td>100</td>
</tr>
<tr>
<td>Burkholderia pseudomallei (strain TES)</td>
<td>100</td>
</tr>
</tbody>
</table>

*a The MBC values were determined by a modified micro-broth dilution assay using snake venom proteins (100, 50, 25, 12.5, 6.25, 3.125 μg/ml). Antimicrobial activity of viperatoxin (VipTx-I and VipTx-II) was determined by MBCs in a solution killing assay against Gram-negative and Gram-positive bacteria.

Fig. 4. The mechanisms of action of antimicrobial protein was postulated by SEM examination. (A) Control – clear architecture, (B–F) The protein (VipTx-II) exerted excellent pore formation (blebs), disintegration of bacterial membranes heavily and release of cellular contents after exposure at 6.25 μg/ml (B. pseudomallei) and 12.25 μg/ml (S. aureus). (G and H) Transmission electron microscopic studies additionally damaged of cell wall and loss of cellular content after 24 h treatment of VipTx-II. Symbol denotes: pf-pore formation, rs-rough surface, md- membrane damage, is-irregular shapes, ns-normal surface, ctrl-control.
Fig. 5. (A and B) Evaluation of MTT-based cytotoxicity of proteins incubated with human cells (THP-1) and various concentrations of VipTx-II after 24 h and 48 h incubation. Control (Ctrl) cells without treatment used as a control. (C and D) Cytotoxicity of protein of VipTx-I on THP-1 cells were incubated with the different concentrations (10,000–39 μg/ml). VipTx-I showed severe reduction of cell proliferation and more toxicity up to 1250 μg/ml than the VipTx-II up to only 5000 μg/ml. Light micrograph showing the normal architecture of THP-1 cells, (E) THP-1 cells without treatment served as a control, (F–H) cells treated with 2500, 5000 and 10,000 μg/ml concentrations of protein VipTx-II caused morphological changes after exposure (Magnification ×20).
towards identifying novel agents to treat infections [43]. Most venomous animals contain a variety of venom proteins which participate in both digestion of prey and venom toxicity. Viperidae snake venoms represent a source of important bioactive molecules that have led to the development of diverse new drugs in clinical scenario. In this study, novel snake venom proteins were purified and designated as “Viperatoxin” (VipTx-I and VipTx-II) from the Indian Russell’s viper (D. russelli russelli). The N-terminal amino acid residues of VipTx-I and VipTx-II were sequenced, and compared with existing sequences in the ExPASY proteomics database using BLAST. The sequence comparison shows that VipTx-II matched 60–86% homology with existing snake venom phospholipase A\textsubscript{2}s (svPLA\textsubscript{2}s). The molecular weight of VipTx-I and VipTX-II slightly differs with the previously reported protein masses from known PLA\textsubscript{2}s. Our results corroborate with the N-terminal sequences of B. neuwiedi pauloensis showed important homology with Asp49 basic myotoxic PLA\textsubscript{2}s from other snake venoms [44]. Whereas, Lys49 PLA\textsubscript{2} (myotoxin I) elucidated from B. atrox venom displays very high level of homology with other Lys49 PLA\textsubscript{2}s, although its primary and three-dimensional structure show some difference in the C-terminal region [45]. Generally, characterized svPLA\textsubscript{2}s have a conserved fold with seven disulfide bridges and a histidine at the catalytic site, with calcium (Ca\textsuperscript{2+}) bound at the active site [11,28,46]. The Russell’s viper svPLA\textsubscript{2} structure also contains a Trp-31-containing loop (residues 25-34), \(\beta\)-wing consisting of double-stranded anti-parallel \(\beta\)-strands (residues 74-85) and C-terminal region 9 (residues 119-133). The crystal structures of complexes with transition analogs provide insights into the potential catalytic mechanisms with the presence of fatty acid in the hydrophobic channel [47].

Several recent studies have shown that antimicrobial proteins and peptides are produced by many living organisms and represent a novel class of antibiotics to treat infectious diseases [8]. Examples include crotonamine, a myotoxin from venom of the South American rattlesnake, which is structurally related to beta-defensins. The later are antimicrobial peptides found in vertebrate animals [13], peptides from Naja naja venom [48], and a venom protein from the inland taipan which all exhibit antimicrobial activity. Previous studies have shown that the naturally occurring proteins display antimicrobial activity [12]. Remarkably, a group of Lys-49 PLA\textsubscript{2}s homologues present in snake venoms [19], are bactericidal even though they lack enzymatic activity. Another study shows that myotoxic PLA\textsubscript{2}s are bactericidal against E. coli and S. aureus [20].

In this study, VipTx-II exerted the most potent action against a multi-drug resistant strain (KHW) of B. pseudomallei as compared to the less resistant TES strains. The inhibitory potential of VipTx-II was quite equivalent to that of standard antibiotics such as streptomycin, chloramphenicol, cefazidime and vancomycin versus VipTx-I. Further, we tested the antibacterial properties of VipTx-II and found that it killed several strains of Gram-positive and Gram-negative bacteria, with doses ranging from (100–0.01 \(\mu\)g/ml). The dose-dependant assay revealed bacterial killing by viper protein within 24 h and reached the maximum (75%) activity at a 10 \(\mu\)g/ml concentration. Our earlier study...
clearly demonstrated that viper proteins exert the most significant bactericidal effects against *B. pseudomallei* [49]. Our study, in contrast with the EcTx-I protein from the venom of Saw-scaled viper species, demonstrated significant bactericidal inhibition of multi-drug resistance (MDR) *B. pseudomallei* (KHW) and *E. aerogenes* previously [38]. VipTx-II exerted the most significant inhibition against *B. pseudomallei* KHW strains even at the lowest dilutions (MICs 6.25 μg/ml). Interestingly, the VipTx-II protein showed very significant inhibitory effects against *S. aureus*, *P. vulgaris* and *P. mirabilis* even at 12.25 μg/ml doses (in a dose-dependent manner). Whereas, recently reported studies show that a basic protein of VRV-PL-V from *Daboia russelli pulchella* (venom PLα2 fraction V) effectively inhibits Gram-positive bacteria such as *S. aureus* and *Bacillus subtilis* at MICs 13-24 μg/ml versus Gram-negative *E. coli*, *Vibrio cholerae*, *Klebsiella pneumoniae* and *Salmonella paratyphi* [50]. Similarly the PLα2 fraction VIIIa of *D. russelli pulchella* (VRV-PL-VIIIa) also controls the growth of bacteria at 11–19 μg/ml doses [51]. BnpTX-I/II is a basic myotoxic PLA2 obtained from *Naja naja atra* (Taiwan cobra) exerts the most potent inhibitory effects against *S. aureus* than *E. coli* [52]. However, the VipTx-II displays the most potent inhibitory effects against *B. pseudomallei* KHW (MICs 6.25 μg/ml) as well as *S. aureus*, *P. vulgaris* and *P. mirabilis* (MICs 12.25 μg/ml) at very low concentrations compared to the existing PLα2S.

We found novel bactericidal mechanisms attributed to viper proteins (VipTx-I and VipTx-II) that induced pore formation on clinical isolates such as MDR *B. pseudomallei* (KHW strain). There were cellular changes that include membrane disintegration. Our study corroborate with membrane damage elicited by the binding of protein to the lipid membrane [53]. Recently, there have been suggestions that transmembrane pore formation is not the only mechanism of microbial killing [54]. Several earlier observations indicate that translocated protein or peptides can alter cytoplasmic membrane septum formation, inhibit cell-wall, nucleic-acid and protein synthesis or inhibit enzymatic activity [54]. Previously study of the mechanisms was clearly evidenced that the antimicrobial protein as well as peptides induced killing of microorganisms by severely damaging membrane and formation of pores on invading pathogens [38]. Therefore, sPLα2 is implicated in the lipid digestion as a host defence mechanism including the observed antibacterial activities [55].

Enzymatically-independent bactericidal effects of PLα2 have been demonstrated and mapped to a specific membrane-damaging protein site [20]. A number of Trp substituted peptides derived from sPLα2 can increase microbicidal potency against both Gram-negative and Gram-positive bacteria [25]. Previous studies also show that the interaction of this peptide with the lipopolysaccharide (LPS) and lipid A or lipoteichoic acid (LA) relies on a membrane-permeabilizing mechanism to exert its bactericidal effects [20]. In addition to Trp, Pro and Arg residues are also important in membrane disruption and/or cell entry. Thus these later Pro and Arg residues are an attractive template for designing novel antimicrobial peptides effective against a broad spectrum of microorganisms [56]. In addition, it has been reported that the insertion of positively-charged amino acids can result in big variations and high antibiotic activity. These peptides also significantly reduce hemolysis and cytotoxicity that correlate with decreased permeabilization of the zwitterionic phosphatidylycholine membrane, the major component of outer leaflets from red blood cells [56].

Several proteins and polypeptides have common cytolytic properties, and these cytolsins provide an offensive armament for the animal defense. In this study, cell survival decreased with the increasing concentrations of viper protein (VipTx-I) at 39–10,000 μg/ml than VipTx-II. However, the enzyme (VipTx-II) has low level of toxicity for eukaryotic cells at higher concentrations. The morphological changes in THP-1 cells show membrane disruption, lysis and significant cell death apparent at 2500 μg/ml with VipTx-I in a time-dependent manner (24 and 48 h). Although, 60% of the cells were killed by the VipTx-I after 48 h, but the observed cytolytic effects were very high at higher protein concentrations (1250 μg/ml). This may be due to the mechanism for clearing free fatty acids that is toxic to the cell for retaining cellular energy reserve. Those fatty acids might be acylated by intracellular located enzymes to membrane-bound proteins. Acylation of these proteins can be potentially one of the mechanisms for disrupting membrane integrity and cellular signaling [57].

### 4.1. Mechanisms of actions

The antimicrobial potency of snake venom is largely unexplored. Naturally occurring snake venom proteins and peptides possess highly potent antimicrobial activity against *B. pseudomallei* [58]. A family of sPLα2 comprised of low molecular weight (13 kDa), disulfide-linked proteins [59] depend on Ca2+ for enzymatic activity and play an important role in innate immunity and killing of bacteria [60]. Antimicrobial proteins/peptides generally kill bacteria by permeabilizing and or disrupting their membranes [61]. The molecular basis for the activity and selectivity of these peptides has been studied in model membranes [61]. Cationic antimicrobial peptides interact preferentially with acidic lipids that are chiefly abundant and found in bacteria [38]. However, the basic proteins manifest strong amphiphilic properties on their molecular surface. For example, apolar tips of loops I-III form a hydrophobic zone flanked by a positively-charged Lys and Arg residues. Another membrane model study demonstrates that the hydrophobic bottom represents a principal membrane-binding motif for protein [62]. In addition, the structural defects in lipid bilayers induced by protein binding to the membrane can lead to the formation of pores [63]. The explanations above provide a basis for the major differences in cell specificity by various antimicrobial peptides/proteins. Interaction of peptides with bilayers alters the organization of the membranes and makes them more permeable to ions [64]. Overall, it is not only the nature of a protein and peptide, but also various characteristics of the cell membrane and metabolic state of the target cell, that ultimately determine the mechanism of antimicrobial activity.

In conclusion, we report for the first time a novel bactericidal protein, VipTx-II, from the crude venom of a Indian Russell’s viper. These protein possessed powerful antibacterial properties against Gram-positive and Gram-negative bacteria, in which VipTx-II was more effective against *S. aureus and B. pseudomallei* (KHW) than VipTx-I. Thus, the studies provide novel insights into the molecular mechanisms of action involving membrane damage and pore formation induced by viper VipTx-II. Furthermore, VipTx-II is not cytotoxic on human macrophages (THP-1) in comparison to VipTx-I. Further studies should help to completely solve the structure of these proteins that can be very useful to elucidate their detailed mechanisms of action in vivo. Thus, the observed antimicrobial activities of viper venom proteins/derived peptides could be further useful for developing potential antimicrobial candidates against drug-resistant Gram-negative and Gram positive bacteria.


